Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market
05 9월 2024 - 7:57PM
Aclarion, Inc.,
(“Aclarion” or the “Company”) (Nasdaq: ACON,
ACONW), a healthcare technology company that is leveraging
biomarkers and proprietary augmented intelligence (AI) algorithms
to help physicians identify the location of chronic low back pain,
announced today the launch of a program to develop a statewide
network of providers in New Jersey to utilize Nociscan throughout
the personal injury and workers compensation population.
Justin Kubeck, MD, an orthopedic surgeon and founder of Ocean
Pain and Spine in Toms River, NJ will initiate a focused effort to
improve the objective evaluation of chronic low back pain patients
throughout the complex personal injury and workers compensation
system that aims to provide the right treatments and financial
compensation to patients suffering from injury.
“The personal injury and workers compensation ecosystem involves
a discrete number of judges and lawyers who work to adjudicate
claims leveraging the expertise of physicians dedicated to
understanding this unique segment of the healthcare system. The
nature of these claims mandates an objective and definitive
diagnosis, knowing that the diagnosis may well be challenged in a
legal setting. The use of Nociscan can be a powerful objective
measurement tool to provide a strong case for supporting an
appropriate treatment pathway,” said Dr. Kubeck. “Over the next
several months, I will be working to educate the network of judges
and lawyers who determine the appropriateness of recommended
treatments on the value Nociscan brings to my patients and the
value I think it can bring to improving the workers compensation
and personal injury evaluation process.”
Workers compensation and personal injury claims involving the
neck and back have significant financial implications for workers,
employers, and insurance companies. Although there are many factors
that go into the final settlement or jury verdict associated with
these cases, whether surgical intervention is required or not is
often a clear delineating point for the size of the settlement.
Because Nociscan directly measures biomarkers in the lumbar disc
correlated to pain and structural integrity, Nociscan is positioned
to provide important objective data that providers can use as they
formulate and defend their recommended treatment
plan.
Ryan Bond, Chief Strategy Officer of Aclarion, commented, “Once
established in New Jersey, we will target other markets throughout
the United States to replicate the success of the NJ market.
We believe this population is the perfect fit for the use of
advanced biomarker identifications correlated to pain and available
exclusively through the Nociscan platform.”
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages
Magnetic Resonance Spectroscopy (“MRS”), proprietary signal
processing techniques, biomarkers, and augmented intelligence
algorithms to optimize clinical treatments. The Company is first
addressing the chronic low back pain market with Nociscan, the
first, evidence-supported, SaaS platform to noninvasively help
physicians distinguish between painful and nonpainful discs in the
lumbar spine. Through a cloud connection, Nociscan receives
magnetic resonance spectroscopy (MRS) data from an MRI machine for
each lumbar disc being evaluated. In the cloud, proprietary signal
processing techniques extract and quantify chemical biomarkers
demonstrated to be associated with disc pain. Biomarker data is
entered into proprietary algorithms to indicate if a disc may be a
source of pain. When used with other diagnostic tools, Nociscan
provides critical insights into the location of a patient’s low
back pain, giving physicians clarity to optimize treatment
strategies. For more information, please visit
www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 about the Company’s current
expectations about future results, performance, prospects and
opportunities. Statements that are not historical facts, such as
“anticipates,” “believes” and “expects” or similar expressions, are
forward-looking statements. These forward-looking statements are
based on the current plans and expectations of management and are
subject to a number of uncertainties and risks that could
significantly affect the Company’s current plans and expectations,
as well as future results of operations and financial condition.
These and other risks and uncertainties are discussed more fully in
our filings with the Securities and Exchange Commission. Readers
are encouraged to review the section titled “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2023, as well as other disclosures contained in the Prospectus
and subsequent filings made with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date and the Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contacts:Kirin M. SmithPCG Advisory,
Inc.646.823.8656ksmith@pcgadvisory.com
Media Contacts:Jodi LambertiSPRIG
Consulting612.812.7477jodi@sprigconsulting.com
Aclarion (NASDAQ:ACON)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Aclarion (NASDAQ:ACON)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024